Home  |  Important Safety Information  |  Full Prescribing Information PDF
Contact Us  |  Site Map
A
A
A
Print

Helpful Resources

Useful PDF references and materials

Full Prescribing Information

Patient Education Materials:
FROVA® Patient Brochure
FROVA® Patient Tear Sheet

Healthcare Provider Materials:
FROVA Slim Jim
Patient Profile #1 — Amy — Recurrence
Patient Profile #2 — Lisa — Efficacy
Patient Profile #3 — Maria — Tolerability
Patient Profile #4 — Jennifer and John — Duration

 Get Adobe® Reader®


Find out more about migraine by visiting these websites

Migraine Resource Network
www.migraineresourcenetwork.com
The Migraine Resource Network is a comprehensive educational initiative for clinicians seeking current and emerging information on migraine headache. This site provides tools, information, and resources that support improved therapeutic outcomes for patients with migraine.

The National Headache Foundation (NHF)
www.headaches.org
Visit the National Headache Foundation website for information about headaches, clinical trials, and more.

American Headache Society Committee on Headache Education
www.achenet.org
Visit the American Headache Society Committee on Headache Education to access assessment tools, educational resources for patients on important topics in headache, and many other useful materials.

Endo Pharmaceuticals Inc.
www.endo.com
Find out about Endo products and new initiatives.

For more information, please see Full Prescribing Information for FROVA at http://www.frova.com/pi.

If you are a Vermont prescriber, additional information is available.

References
  1. Kelman L. Pain characteristics of the acute migraine attack. Headache. 2006;46(6):942-953.
  2. Malik SN, Hopkins M, Young WB, Silberstein SD. Acute migraine treatment: patterns of use and satisfaction in a clinical population. Headache. 2006;46(5):773-780.
  3. Headache Classification Subcommittee of the International Headache Society (IHS). The international classification of headache disorders. Cephalalgia. 2004;24(suppl 1):8-160.
  4. Guidelines for controlled trials of drugs in migraine. First edition. International Headache Society Committee on Clinical Trials in Migraine. Cephalalgia. 1991;11(1):1-12.
  5. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646-657.
  6. Cady R, Elkind A, Goldstein J, Keywood C. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate to severe. Curr Med Res Opin. 2004;20(9):1465-1472. doi:10.1185/030079904X2745.
  7. Ryan R, Geraud G, Goldstein J, Cady R, Keywood C. Clinical efficacy of frovatriptan: placebo-controlled studies. Headache. 2002;42(suppl 2):S84-S92.
  8. FROVA® [package insert]. Chadds Ford, PA: Endo Pharmaceuticals, Inc; 2007.
  9. Physicians' Desk Reference. 65th ed. Montvale, NJ: Physicians' Desk Reference Inc; 2011.
  10. RELPAX® [package insert]. New York, NY: Pfizer Inc; 2008.
  11. Granella F, Sances G, Zanferrari C, Costa A, Martignoni E, Manzoni GC. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache. 1993;33(7):385-389.
  12. Dzoljic E, Sipetic S, Vlajinac H, et al. Prevalence of menstrually related migraine and nonmigraine primary headache in female students of Belgrade University. Headache. 2001;42(3):185-193.
  13. Granella F, Sances G, Pucci E, Nappi RE, Ghiotto N, Nappi G. Migraine with aura and reproductive life events: a case control study. Cephalalgia. 2000;20(8):701-707.
  14. Couturier EG, Bomhof MA, Neven AK, van Dukin NP. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia. 2003;23(4):302-308.
  15. Granella F, Sances G, Allais G, et al. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia. 2004;24(9):707-716.
  16. MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology. 2004;63(2):351-353.
  17. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology. 2006;67(12):2154-2158.
  18. Wober C, Brannath W, Schmidt K, et al; for the PAMINA Study Group. Prospective analysis of factors related to migraine attacks: the PAMINA study. Cephalalgia. 2007;27(4):304-314.
  19. US Department of Health and Human Services, Office on Women's Health. Migraine. http://www.womenshealth.gov/faq/migraine.pdf. Accessed June 29, 2010.